OFFICAL PROJECT SITE
Novel Target for Treatment of Chronic Inflammatory Diseases — Notid
Pernilla Abrahamsson joins as Chief Operating Officer
Press release may 7, 2019 ”Lipum is a very interesting company in an exciting development. Soon in the clinical phase and I am looking forward to all challenges ahead of us”, says Pernilla Abrahamsson. […]
Umeå life science company attends world congress –
“Our product has huge potential”
Press release April 23, 2019 Umeå life science company Lipum will participate in one of the world's largest congresses for rheumatic diseases this June. “The elite of our industry gathers at this congress once a year and competition is incredibly intense. It’s important to be seen there”, says Einar Pontén, [...]
Lipum attracts interest from life science leaders
Lipum is attending two significant events in Vienna next week. At the RESI Europe and the BIO-Europe Spring meetings we will meet with key decision makers from the pharma and venture capital segments. These events take place March 25-27 and provides an opportunity to meet, please contact us and learn [...]
Lipum and Abzena sign integrated CMC agreement
Press release march 19 2019 Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel [...]
Umeåföretag tar nästa steg mot ett nytt läkemedel
Pressrelease 3 juni, 2019 Ladda ned pressrelase: Investerare satsar 25 MSEK på nytt läkemedel (pdf) » Umeåföretaget Lipum utvecklar ett biologiskt läkemedel för behandling av kroniska inflammationer. Tidigare pre-kliniska studier har visat mycket goda resultat och potential att ge en bättre behandling av till exempel ledgångsreumatism. ”Konkurrensen i branschen är [...]
Lipum to NASDAQ
On 6-7 March, Lipum attends a pitching event for Deep Tech companies in Stockholm hosted by The European Innovation Council (EIC) pilot and Nasdaq. The event is exclusively organised for EIC pilot- funded companies with the opportunity to pitch their business to top European investors and connect with Nasdaq representatives [...]
Program:
European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741
Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases
Project budget:
3.2 M€
Funding from the EU:
2.2 M€
Start:
2018-11-01
End:
2020-11-30